4 results on '"Dos Santos, Edmilson"'
Search Results
2. Inhibitory effect of O-propargyllawsone in A549 lung adenocarcinoma cells.
- Author
-
dos Santos, Edmilson Willian Propheta, de Sousa, Rauan Cruz, de Franca, Mariana Nobre Farias, Santos, Jileno Ferreira, Ottoni, Flaviano Melo, Isidório, Raquel Geralda, de Lucca Junior, Waldecy, Alves, Ricardo José, Scher, Ricardo, and Corrêa, Cristiane Bani
- Subjects
PHYTOTHERAPY ,THERAPEUTIC use of antineoplastic agents ,ADENOCARCINOMA ,LUNG cancer ,QUINONE ,WOUND healing ,FLOW cytometry ,STAINS & staining (Microscopy) ,ANALYSIS of variance ,COLONY-forming units assay ,HEMOLYSIS & hemolysins ,ANTINEOPLASTIC agents ,APOPTOSIS ,CELL motility ,LEAVES ,CELL lines ,PLANT extracts ,MOLECULAR structure ,ERYTHROCYTES ,DATA analysis software ,NECROSIS ,CELL death ,PHARMACODYNAMICS - Abstract
Background: Lung cancer is the deadliest type of cancer in the world and the search for compounds that can treat this disease is highly important. Lawsone (2-hydroxy-1,4-naphtoquinone) is a naphthoquinone found in plants from the Lawsone genus that show a high cytotoxic effect in cancer cell lines and its derivatives show an even higher cytotoxic effect. Methods: Sulforhodamine B was used to evaluate the cytotoxic activity of compounds on tumor cells. Clonogenic assay was used to analyze the reduction of colonies and wound healing assay to the migratory capacity of A549 cells. Apoptosis and necrosis were analyzed by flow cytometer and Giemsa staining. Hemolysis assay to determine toxicity in human erythrocytes. Results: Lawsone derivatives were evaluated and compound 1 (O-propargyllawsone) was the one with the highest cytotoxic effect, with IC
50 below 2.5 µM in A549 cells. The compound was able to reduce colony formation and inhibit cell migration. Morphological changes and cytometry analysis show that the compound induces apoptosis and necrosis in A549 cells. Conclusions: These results show that O-propargyllawsone show a cytotoxic effect and may induce apoptosis in A549 cells. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
3. Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.
- Author
-
Ozorio dos Santos, Edmilson, Correa Carneiro-Lobo, Tatiana, Nobrega Aoki, Mateus, Levantini, Elena, and Sanchez Bassères, Daniela
- Subjects
- *
GENETIC mutation , *LUNG cancer , *WESTERN immunoblotting , *TUMOR growth , *CANCER treatment , *CLINICAL trials , *ONCOGENES - Abstract
Background: Activating mutations in KRAS are prevalent in lung cancer and have been causally linked to the oncogenic process. However, therapies targeted to oncogenic RAS have been ineffective to date and identification of KRAS targets that impinge on the oncogenic phenotype is warranted. Based on published studies showing that mitotic kinases Aurora A (AURKA) and B (AURKB) cooperate with oncogenic RAS to promote malignant transformation and that AURKA phosphorylates RAS effector pathway components, the aim of this study was to investigate whether AURKA and AURKB are KRAS targets in lung cancer and whether targeting these kinases might be therapeutically beneficial. Methods: In order to determine whether oncogenic KRAS induces Aurora kinase expression, we used qPCR and western blotting in three different lung cell-based models of gain- or loss-of-function of KRAS. In order to determine the functional role of these kinases in KRAS-induced transformation, we generated KRAS-positive A549 and H358 cells with stable and inducible shRNA-mediated knockdown of AURKA or AURKB and evaluated transformation in vitro and tumor growth in vivo. In order to validate AURKA and/or AURKB as therapeutically relevant KRAS targets in lung cancer, we treated A549 and H358 cells, as well as two different lung cell based models of gain-of-function of KRAS with a dual Aurora kinase inhibitor and performed functional in vitro assays. Results: We determined that KRAS positively regulates AURKA and AURKB expression. Furthermore, in KRAS-positive H358 and A549 cell lines, inducible knockdown of AURKA or AURKB, as well as treatment with a dual AURKA/AURKB inhibitor, decreased growth, viability, proliferation, transformation, and induced apoptosis in vitro. In addition, inducible shRNA-mediated knockdown of AURKA in A549 cells decreased tumor growth in vivo. More importantly, dual pharmacological inhibiton of AURKA and AURKB reduced growth, viability, transformation, and induced apoptosis in vitro in an oncogenic KRAS-dependent manner, indicating that Aurora kinase inhibition therapy can specifically target KRAS-transformed cells. Conclusions: Our results support our hypothesis that Aurora kinases are important KRAS targets in lung cancer and suggest Aurora kinase inhibition as a novel approach for KRAS-induced lung cancer therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
4. IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.
- Author
-
Carneiro-Lobo, Tatiana Correa, Scalabrini, Luiza Coimbra, Magalhães, Leila da Silva, Cardeal, Laura B., Rodrigues, Felipe Silva, dos Santos, Edmilson Ozorio, Baldwin, Albert S., Levantini, Elena, Giordano, Ricardo J., and Bassères, Daniela Sanchez
- Subjects
- *
VASCULAR endothelial growth factors , *LUNG cancer - Abstract
Highlights • IKKβ promotes KRAS-induced proangiogenic IL-8 and VEGF expression and secretion. • IKKβ promotes KRAS-induced endothelial cell migration, invasion and tube formation. • IKKβ targeting reduces KRAS-mutant lung tumor growth and angiogenesis. • IKKβ targeting reduces pathological angiogenesis in a cancer-independent model. Abstract Objectives The ability of tumor cells to drive angiogenesis is an important cancer hallmark that positively correlates with metastatic potential and poor prognosis. Therefore, targeting angiogenesis is a rational therapeutic approach and dissecting proangiogenic pathways is important, particularly for malignancies driven by oncogenic KRAS, which are widespread and lack effective targeted therapies. Based on published studies showing that oncogenic RAS promotes angiogenesis by upregulating the proangiogenic NF-κB target genes IL-8 and VEGF, that NF-κB activation by KRAS requires the IKKβ kinase, and that targeting IKKβ reduces KRAS-induced lung tumor growth in vivo , but has limited effects on cell growth in vitro , we hypothesized that IKKβ targeting would reduce lung tumor growth by inhibiting KRAS-induced angiogenesis. Materials and methods To test this hypothesis, we targeted IKKβ in KRAS-mutant lung cancer cell lines either by siRNA-mediated transfection or by treatment with Compound A (CmpdA), a highly specific IKKβ inhibitor, and used in vitro and in vivo assays to evaluate angiogenesis. Results and conclusions Both pharmacological and siRNA-mediated IKKβ targeting in lung cells reduced expression and secretion of NF-κB-regulated proangiogenic factors IL-8 and VEGF. Moreover, conditioned media from IKKβ-targeted lung cells reduced human umbilical vein endothelial cell (HUVEC) migration, invasion and tube formation in vitro. Furthermore, siRNA-mediated IKKβ inhibition reduced xenograft tumor growth and vascularity in vivo. Finally, IKKβ inhibition also affects endothelial cell function in a cancer-independent manner, as IKKβ inhibition reduced pathological retinal angiogenesis in a mouse model of oxygen-induced retinopathy. Taken together, these results provide a novel mechanistic understanding of how the IKKβ pathway affects human lung tumorigenesis, indicating that IKKβ promotes KRAS-induced angiogenesis both by cancer cell-intrinsic and cancer cell-independent mechanisms, which strongly suggests IKKβ inhibition as a promising antiangiogenic approach to be explored for KRAS-induced lung cancer therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.